Thank you for sharing!

Your article was successfully shared with the contacts you provided.

PRINCETON, NJ-Following its acquisition of Wyeth, Pfizer Inc. announced this morning that it plans to close its Princeton, NJ R&D campus. According to a company release, the company will consolidate to five main research sites in Cambridge, MA; Groton, CT; Pearl River, NY; La Jolla, CA; and Sandwich, UK and three research-oriented labs in San Francisco, Cambridge, UK and Shanghai, China.

“By focusing our R&D operations in these centers, we are building the world’s premier biopharmaceutical R&D enterprise,” says Mikael Dolsten, president of BioTherapeutics Research & Development, in a statement. “This new structure puts Pfizer in the best position to conduct cutting-edge research within and beyond our own laboratories and to deliver a portfolio of high-impact medicines to patients.”

As part of the consolidation, Pfizer will move a number of functions from Collegeville, PA.; Pearl River, NY; and St. Louis to other locations and will discontinue R&D operations in Princeton; Chazy, Rouses Point and Plattsburgh, NY; Sanford and Research Triangle Park, NC; and Gosport, Slough/Taplow, UK. In addition, Pfizer will consolidate R&D functions from its New London, CT site to its nearby research facility in Groton.

As a result of these changes, Pfizer said it will cut its global R&D square footage by 35%. R&D activities will now be conducted at five main sites and nine specialized units around the world as compared with 20 currently.

In an article in the Star-Ledger, Dolsten says that New Jersey will continue to be an important area for Pfizer. “But when it comes to research and development, we have decided to exit our presence.” Dolsten says. “We’re trying to create a structure that will be efficient and focused on fewer geographies.”

When the merger between Pfizer and Wyeth, which was based in Madison, NJ, was announced in January, Pfizer said it intended to reduce its global workforce by approximately 10%, or roughly 8,000 jobs.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?



Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt

Copyright © 2022 ALM Global, LLC. All Rights Reserved.